39 published articles
On April 22, 2026, the FDA removed BPC-157 from Category 2 of the 503A bulk drug substances list, ending its interim compounding authorization. For protocol designers targeting ulcerative colitis or chronic pain, licensed compounding is no longer legally straightforward. Rebuilding requires mapping mechanistic substitutes — primarily KPV, TB-500, and GHK-Cu — against the pathways BPC-157 previously covered.
Based on preclinical data available through 2026, BPC-157 and TB-500 drive tendon and ligament repair through mechanistically distinct angiogenic pathways — neither compound has been validated in a controlled human trial. BPC-157 operates via FAK-paxillin and VEGFR2 signalling at the injury site; TB-500 acts systemically through G-actin sequestration and endothelial progenitor cell recruitment. No head-to-head RCT exists.
No direct co-administration trial for semaglutide and thymosin alpha-1 (Tα1) exists as of 2026. The interaction map is built from each compound's independent pharmacology: semaglutide's GLP-1R–mediated anti-inflammatory signaling and Tα1's TLR-dependent immune priming operate through non-overlapping receptor systems, making a direct pharmacodynamic collision unlikely but formally uncharacterised.